Biosimilars: Prioritising the Emerging Market Opportunity
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
By 2015, approximately USD73 billion of biologic sales are projected to lose patent protection, opening the door for the entry of biosimilar versions of these agents. The majority of agents losing patent protection within this time period are more complex biologics such as monoclonal antibodies (mAbs) and fusion proteins. Given the complexity and uncertainty of the biosimilar regulatory landscape in the developed markets -particularly the USA -as well as the high cost of clinical development in these markets, many potential biosimilar manufacturers are looking to the emerging markets (EM) as a high commercial opportunity. Success within these markets is driven by market issues unique to these markets.
Have Your Say
Rate this feature and give us your feedback in the comments section below
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.